iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
9.95
-0.07 (-0.70%)
Jun 27, 2025, 4:00 PM - Market closed
iTeos Therapeutics Employees
iTeos Therapeutics had 173 employees as of December 31, 2024. The number of employees increased by 16 or 10.19% compared to the previous year.
Employees
173
Change (1Y)
16
Growth (1Y)
10.19%
Revenue / Employee
$202,312
Profits / Employee
-$756,133
Market Cap
380.82M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ITOS News
- 4 weeks ago - iTeos Therapeutics Announces Its Intention to Wind Down Operations - GlobeNewsWire
- 6 weeks ago - iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 2 months ago - iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewsWire
- 4 months ago - iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless - Seeking Alpha
- 6 months ago - iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 - Seeking Alpha
- 7 months ago - iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress - GlobeNewsWire